Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu
aneb sacubitril-valsartan

J 2019

Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan

VÍTOVEC, Jiří; Jindřich ŠPINAR a Lenka ŠPINAROVÁ

Základní údaje

Originální název

Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan

Autoři

VÍTOVEC, Jiří; Jindřich ŠPINAR a Lenka ŠPINAROVÁ

Vydání

Interni Medicina pro Praxi, SOLEN s.r.o. 2019, 1212-7299

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.36290/int.2019.044

EID Scopus

2-s2.0-85088612435

Klíčová slova anglicky

Dual inhibition; Heart failure; Sacubitril-valsartan

Změněno: 5. 5. 2022 18:01, JUDr. Sabina Gajdzioková

Anotace

V originále

Dual antagonist of AT1 receptors for angiotensin II (ARB) and neprilysin, generic name sacubitril valsartan (formaly LCZ 696 or angiotensin receptor blocker and neprilysin inhibitor - ARNI) was clinicaly tested in the treatmet of hypertension and heart failure. The mechanism of action is in the blockade of AT1 receptros by valsartan in combination with decreased degradation of natriuretic peptides with increased vasodilatation. The first clinical trial PARAMOUNT with LCZ696 in the treatment of Heart failure patients with preserved ejection fraction has whown significant decrea-se of NT-proBNP concentrations. Clinical trial PARADIGM-HF in patients with decreased ejection fraction and high natriuretic peptides levels was fi-nished prematuraly for a positive effect of LCZ696 both on mortality and morbidity if compared with enalapril. Cardiovascular mortality was decreased by 20%, first hospitalisation for Heart failure by 21%. The PARAGON-HF study is testing the effect of sacubitril valsartan in patients with preserved ejection fraction

Citovat

VÍTOVEC, Jiří; Jindřich ŠPINAR a Lenka ŠPINAROVÁ. Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan. Interni Medicina pro Praxi. SOLEN s.r.o., 2019, roč. 21, č. 2, s. 118 - 124. ISSN 1212-7299. Dostupné z: https://doi.org/10.36290/int.2019.044.

@article{1726980,
   author = {Vítovec, Jiří and Špinar, Jindřich and Špinarová, Lenka},
   article_number = {2},
   doi = {https://doi.org/10.36290/int.2019.044},
   keywords = {Dual inhibition; Heart failure; Sacubitril-valsartan},
   language = {cze},
   issn = {1212-7299},
   journal = {Interni Medicina pro Praxi},
   title = {Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan},
   url = {https://www.internimedicina.cz/pdfs/int/2019/02/11.pdf},
   volume = {21},
   year = {2019}
}

TY  - JOUR
ID  - 1726980
AU  - Vítovec, Jiří - Špinar, Jindřich - Špinarová, Lenka
PY  - 2019
TI  - Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan
JF  - Interni Medicina pro Praxi
VL  - 21
IS  - 2
SP  - 118 - 124
EP  - 118 - 124
PB  - SOLEN s.r.o.
SN  - 12127299
KW  - Dual inhibition
KW  - Heart failure
KW  - Sacubitril-valsartan
UR  - https://www.internimedicina.cz/pdfs/int/2019/02/11.pdf
N2  - Dual antagonist of AT1 receptors for angiotensin II (ARB) and neprilysin, generic name sacubitril valsartan (formaly LCZ 696 or angiotensin receptor blocker and neprilysin inhibitor - ARNI) was clinicaly tested in the treatmet of hypertension and heart failure. The mechanism of action is in the blockade of AT1 receptros by valsartan in combination with decreased degradation of natriuretic peptides with increased vasodilatation. The first clinical trial PARAMOUNT with LCZ696 in the treatment of Heart failure patients with preserved ejection fraction has whown significant decrea-se of NT-proBNP concentrations. Clinical trial PARADIGM-HF in patients with decreased ejection fraction and high natriuretic peptides levels was fi-nished prematuraly for a positive effect of LCZ696 both on mortality and morbidity if compared with enalapril. Cardiovascular mortality was decreased by 20%, first hospitalisation for Heart failure by 21%. The PARAGON-HF study is testing the effect of sacubitril valsartan in patients with preserved ejection fraction
ER  -

VÍTOVEC, Jiří; Jindřich ŠPINAR a Lenka ŠPINAROVÁ. Duální inhibice AT1 receptoru pro angiotenzin II~a~neprilysinu aneb sacubitril-valsartan. \textit{Interni Medicina pro Praxi}. SOLEN s.r.o., 2019, roč.~21, č.~2, s.~118 - 124. ISSN~1212-7299. Dostupné z: https://doi.org/10.36290/int.2019.044.

Přehled o publikaci